|
About our scientists
 Professor John Hamilton, Program Leader Program 2 and Program 4
John obtained his PhD in Chemistry and a Doctorate of Science from the University of Melbourne. He has worked in the Basel Institute for Immunology, the Ontario Cancer Institute, Rockefeller University and Sloan Kettering Institute for Cancer Research.
Since returning to Australia from that period, he was founding CEO for our CRC, and he is also at the University of Melbourne, Department of Medicine, Royal Melbourne Hospital as a Fellow of the National Health and Medical Research Council of Australia. In addition, he is a Professorial Fellow at the University of Melbourne and the Director of the Arthritis and Inflammation Research Centre in the University. The main focus of his current research is the control of development of cells of the monocyte/macrophage lineage and the function of this lineage in inflammatory disease. |
Professor Gary Anderson and Program Leader Program 1
Gary is the Program Leader for Research Program 1, which studies the role of macrophages in inflammatory diseases. Gary completed his PhD in pharmacology at the University of Melbourne in 1990. In 1997, Gary worked as the Group leader in respiratory pharmacology at Novartis Pharmaceuticals in Switzerland. Since 1997, Gary has worked at the University of Melbourne, and currently heads up a laboratory in the Department of Pharmacology. |
 |
 |
Dr Steven Bozinovski, Project Leader Project 1, Program 1
Steven completed his PhD in Biochemistry at the University of Melbourne in 2000. Since then, he has worked for the University of Melbourne and is currently a Project Leader for the CRC, looking at ‘Analysis of Human Chronic Obstructive Pulmonary Disease Tissues and Cells’ in Gary Anderson’s laboratory. |
 |
Dr Ross Vlahos, Project Leader Project 3, Program 1
Ross completed his PhD in Pharmacology at the University of Melbourne in 1996. Since then, he has worked in research at the Bernard O’Briend Institute of Microsurgery at St Vincent’s Hospital in Melbourne; and for the Department of Pharmacology at the University of Melbourne, where he heads up one of CRC projects, looking at ‘Murine Chronic Obstructive Pulmonary Disease models’. |
 |
Dr Andrew Cook, Project Leader Project 4, Program 1
Andrew worked as a Research Fellow at Lund University in Sweden between 1997-1998 looking at the ‘Genetics of arthritis and multiple sclerosis’. Since then, he has worked at the University of Melbourne, Department of Medicine, and is currently a project leader for the CRC in ‘Murine arthritis and surrogate models’. |
| Dr Bernadette Scott, Project Leader Project , Program 2 |
 |
Dr Caryn Elsegood, Project Leader Project 2, Program 2
Between 1986 and 1994, Caryn worked in the Department of Chemistry and then the Department of Physiology at the University of WA. From 1995-1999, Caryn completed her Doctorate in Physiology with a NHMRC Dora Lush Postgraduate Biomedical Research Scholarship at the University of WA. In 2000, Caryn joined the Arthritis and Inflammation Research Centre at the University of Melbourne, where she studying ‘Mechanisms of survival of macrophages in response to ingestion of non-degradable particles’. Caryn was a visiting Training Scientist at the Department of Bone Biology, Merck Research Laboratories, Pennsylvania, USA, in 2001-2002. Caryn is currently at the Department of Medicine, University of Melbourne, where she is a Project Leader for the CRC. Her project is ‘Macrophage survival and proliferation’. |
Dr Matthew Sweet, Project Leader Project 3, Program 2
Matthew undertook his PhD at the University of Queensland, with David Hume, where he investigated transcriptional control of the HIV-1 long terminal repeat in macrophages and the characterisation of LPS-responsive elements and transcription factors that direct LPS-inducible HIV-1 promoter activity. After completing his PhD, Matthew continued to work within David Hume’s laboratory as a post doctorate for two years. He then took up a CJ Martin Fellowship for two years working at the University of Glasgow in Scotland with Professor Eddy Liew. Since returning to the University of Queensland, Matthew has taken up the role of Project Leader with the CRC. His project is ‘Macrophage activation and recruitment’. |
 |
Professor Paul Hertzog, Program Leader Program 3 |
|
Associate Professor Stuart Kellie, Deputy CEO, Program Leader Program 3
Stuart received his PhD in experimental pathology from University of St. Andrews in 1980, followed by postdoctoral positions at University of Leicester and the Imperial Cancer Research Fund Laboratories (London) and an EMBO fellowship to work at the Ludwig Institute for Cancer Research, Berne, Switzerland. From 1986-1990 he was Lecturer in Biochemistry at the Royal College of Surgeons of England, and from 1990-2002 he was Group Leader at the Yamanouchi Research Institute (Oxford), where he identified and developed inhibitors to targets in human diseases. He was also a committee member and Treasurer of the British Society for Cell Biology for 10 years.
Stuart moved to University of Queensland in late 2002 to take up his current positions. Within the CRC, Stuart is responsible for target validation, and interacts closely with industrial partners. His scientific interests are in intracellular signalling, particularly tyrosine phosphorylation and tyrosine phosphatases, and he has more than 50 peer-reviewed publications and four patents in this area. Outside interests are football (played with a round ball and using the feet!) and looking after kids and dogs. |
|
Dr Trevor Wilson, Project Leader Project 2 Program 3
Trevor gained his PhD in Immunology from Monash University in 1990. He then completed a PostDoctorate at the University of California in Davis working on autoimmune disease (Scleroderma and SLE) before returning to Monash Department of Obstetrics and Gynaecology. He has been a member of the Centre for Functional Genomics at the Monash Institute for Medical Research since 1995 and has a vast amount of experience in the development and analysis of genetically modified animal models for the investigation of gene function and human disease. He is currently pursuing a number of research interests focusing on Ets1 and Ets2, two factors that may be relevant to the regulation of the immune function. Trevor is a project leader for the CRC. |
|
Dr Ian Cassady, Co-Program Leader Program 4
Ian is a Senior Research Fellow in the Institute for Molecular Bioscience at the University of Queensland and holds a teaching position in the School of Molecular and Microbial Sciences also at UQ. Ian is the co-Program Leader for the CRC's bone research program, Program 4. Ian trained as a molecular and cell biologist at the University of Adelaide before moving to Brisbane to work on the characterisation of genes associated with the macrophages differentiation program. He pursued this work on osteoclast biology at Duke University Medical Center, NC, USA. Since then, Ian has centred his research on osteoclast biology including studies of transcriptional regulation in osteoclasts and the characterisation of the biology of osteoclast marker genes as well as working on the development of novel bone biomaterials. |
Professor David Hume, Consultant
After completing his PhD at the Australian National University, David has had a long and prestigious career. He is Program Leader for the CRC’s Computational Biology and Structural/Functional Genomics work. In addition, his past appointments include:
- Professorial Research Fellow, Institute for Molecular Bioscience/School of Molecular and Microbial Sciences, University of Queensland
- Director, ARC Special Research Centre for Functional and Applied Genomics
- Director, Transgenic Animals Service Queensland
- Elected member – Asia Pacific International Molecular Biology Network
|
 |
|
In the 1970s, David was a Research Fellow at the Max Planck Institut for Immunobiologie, Freiburg Germany and at Oxford University. He has also worked as a Research Fellow at the John Curtain School of Medical Research, Canberra, the MD Anderson Hospital and Turner Institute in Houston and from 1988-1996, in various positions at the University of Queensland.
In 1996, David was the Visiting Fellow at the Department of Molecular Genetics at Ohio State University in Columbus and then in 2000, at the University of Washington. Currently, David heads up the Hume Laboratory at the University of Queensland. The research interests of the Hume Laboratory centre on the biology of macrophages and osteoclasts. Macrophages are cells of theinnate immune system that have critical roles in regulating not only immune response but tissue development and homeostasis.
Following his roles at The University of Queensland and as Program Leader in the CRC, in May 2007, David took up the role of Head of The Roslin Institute in Scotland. His valuble insights remain available to us in a consultancy role.
|
Find out more about our research into chronic inflammatory diseases |
|
|
